LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Search

IQVIA Holdings Inc

Gesloten

SectorGezondheidszorg

231.41 -0.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

230.62

Max

231.72

Belangrijke statistieken

By Trading Economics

Inkomsten

66M

332M

Verkoop

83M

4.1B

K/W

Sectorgemiddelde

31.343

79.874

Winstmarge

8.098

Werknemers

91,000

EBITDA

102M

883M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+2.15% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.4B

39B

Vorige openingsprijs

231.68

Vorige sluitingsprijs

231.41

Nieuwssentiment

By Acuity

49%

51%

167 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

IQVIA Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 nov 2025, 16:49 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 nov 2025, 15:32 UTC

Acquisities, Fusies, Overnames

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 nov 2025, 23:50 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 nov 2025, 23:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 nov 2025, 16:05 UTC

Marktinformatie

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 nov 2025, 16:04 UTC

Marktinformatie

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 nov 2025, 15:54 UTC

Acquisities, Fusies, Overnames

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 nov 2025, 15:44 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 nov 2025, 15:43 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 nov 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 nov 2025, 15:41 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 nov 2025, 15:11 UTC

Marktinformatie

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 nov 2025, 14:26 UTC

Marktinformatie

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 nov 2025, 14:11 UTC

Marktinformatie

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 nov 2025, 14:11 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

27 nov 2025, 13:35 UTC

Marktinformatie

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 nov 2025, 13:33 UTC

Marktinformatie

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 nov 2025, 13:22 UTC

Marktinformatie

Global Equities Roundup: Market Talk

27 nov 2025, 13:22 UTC

Marktinformatie

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 nov 2025, 13:17 UTC

Marktinformatie

LVMH Should Be Able to Recover Next Year -- Market Talk

27 nov 2025, 11:13 UTC

Marktinformatie

European Gas Prices Come Under Pressure -- Market Talk

27 nov 2025, 11:07 UTC

Winsten

Genting: Positive About Prospects Over Longer Term

27 nov 2025, 11:06 UTC

Winsten

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 nov 2025, 11:04 UTC

Winsten

Genting: International Travel Demand Expected to Remain Resilient

27 nov 2025, 11:04 UTC

Winsten

Genting: Global Growth Expected to Remain Subdued

27 nov 2025, 11:04 UTC

Winsten

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 nov 2025, 10:59 UTC

Winsten

Genting Bhd 3Q Net Profit Fell 86% on Year

27 nov 2025, 10:58 UTC

Winsten

Genting Bhd 3Q Rev Rose 14% on Year

27 nov 2025, 10:56 UTC

Winsten

Genting Bhd 3Q Net MYR30.3M

27 nov 2025, 10:56 UTC

Winsten

Genting Bhd 3Q EPS MYR0.0079

Peer Vergelijking

Prijswijziging

IQVIA Holdings Inc Prognose

Koersdoel

By TipRanks

2.15% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 236.79 USD  2.15%

Hoogste 265 USD

Laagste 200 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor IQVIA Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

13

Buy

3

Hold

0

Sell

Technische score

By Trading Central

150.68 / 153.45Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

167 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat